AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
AbbVie (ABBV) and ADARx Pharmaceuticals have announced a strategic collaboration and license option agreement to develop next-generation small interfering RNA (siRNA) therapeutics across neuroscience, immunology, and oncology. ADARx will receive a $335 million upfront payment and could earn several billion dollars in additional contingent payments, option fees, milestones, and tiered royalties.
The partnership combines AbbVie's expertise in biotherapeutic drug development and commercialization with ADARx's proprietary RNA technology. The collaboration focuses on developing siRNA therapeutics, which regulate gene expression by targeting messenger RNA to prevent disease-causing protein production. ADARx's technology enables sustained and precise mRNA silencing, while AbbVie contributes its expertise in antibody engineering and drug delivery approaches.
AbbVie (ABBV) e ADARx Pharmaceuticals hanno annunciato una collaborazione strategica e un accordo di licenza opzionale per sviluppare terapie di nuova generazione basate su RNA a interferenza piccola (siRNA) nei settori delle neuroscienze, immunologia e oncologia. ADARx riceverà un pagamento anticipato di 335 milioni di dollari e potrà guadagnare diverse miliardi di dollari aggiuntivi attraverso pagamenti condizionati, commissioni per l'opzione, traguardi e royalties a scaglioni.
La partnership unisce l'esperienza di AbbVie nello sviluppo e commercializzazione di farmaci bioterapeutici con la tecnologia proprietaria di RNA di ADARx. La collaborazione si concentra sullo sviluppo di terapie siRNA, che regolano l'espressione genica agendo sull'RNA messaggero per impedire la produzione di proteine responsabili di malattie. La tecnologia di ADARx consente un silenziamento dell'mRNA duraturo e preciso, mentre AbbVie apporta la sua competenza nell'ingegneria degli anticorpi e nelle strategie di somministrazione dei farmaci.
AbbVie (ABBV) y ADARx Pharmaceuticals han anunciado una colaboración estratégica y un acuerdo de opción de licencia para desarrollar terapias de ARN de interferencia pequeña (siRNA) de próxima generación en neurociencia, inmunología y oncología. ADARx recibirá un pago inicial de 335 millones de dólares y podría obtener varios miles de millones adicionales mediante pagos contingentes, tarifas por la opción, hitos y regalías escalonadas.
La asociación combina la experiencia de AbbVie en el desarrollo y comercialización de fármacos bioterapéuticos con la tecnología propietaria de ARN de ADARx. La colaboración se centra en desarrollar terapias siRNA que regulan la expresión génica al dirigirse al ARN mensajero para evitar la producción de proteínas causantes de enfermedades. La tecnología de ADARx permite un silenciamiento del ARNm sostenido y preciso, mientras que AbbVie aporta su experiencia en ingeniería de anticuerpos y métodos de administración de fármacos.
AbbVie (ABBV)와 ADARx Pharmaceuticals는 신경과학, 면역학, 종양학 분야에서 차세대 소형 간섭 RNA(siRNA) 치료제 개발을 위한 전략적 협력 및 라이선스 옵션 계약을 발표했습니다. ADARx는 3억 3,500만 달러의 선급금을 받고 추가로 수십억 달러의 조건부 지급금, 옵션 수수료, 마일스톤, 그리고 단계별 로열티를 받을 수 있습니다.
이번 파트너십은 AbbVie의 생물치료제 개발 및 상업화 전문성과 ADARx의 독자적인 RNA 기술을 결합합니다. 협력은 siRNA 치료제 개발에 초점을 맞추고 있으며, 이는 메신저 RNA를 표적으로 하여 질병을 유발하는 단백질 생성을 차단함으로써 유전자 발현을 조절합니다. ADARx의 기술은 지속적이고 정밀한 mRNA 침묵을 가능하게 하며, AbbVie는 항체 공학 및 약물 전달 방식에 대한 전문 지식을 제공합니다.
AbbVie (ABBV) et ADARx Pharmaceuticals ont annoncé une collaboration stratégique et un accord d'option de licence pour développer des thérapies de nouvelle génération basées sur l'ARN interférent petit (siRNA) dans les domaines des neurosciences, de l'immunologie et de l'oncologie. ADARx recevra un paiement initial de 335 millions de dollars et pourrait percevoir plusieurs milliards de dollars supplémentaires sous forme de paiements conditionnels, de frais d'option, de jalons et de redevances échelonnées.
Ce partenariat combine l'expertise d'AbbVie dans le développement et la commercialisation de médicaments biothérapeutiques avec la technologie propriétaire d'ARN d'ADARx. La collaboration se concentre sur le développement de thérapies siRNA, qui régulent l'expression génique en ciblant l'ARN messager pour empêcher la production de protéines responsables de maladies. La technologie d'ADARx permet un silence de l'ARNm durable et précis, tandis qu'AbbVie apporte son expertise en ingénierie des anticorps et en méthodes d'administration des médicaments.
AbbVie (ABBV) und ADARx Pharmaceuticals haben eine strategische Zusammenarbeit und eine Lizenzoptionsvereinbarung angekündigt, um neuartige small interfering RNA (siRNA)-Therapeutika in den Bereichen Neurowissenschaften, Immunologie und Onkologie zu entwickeln. ADARx erhält eine Vorabzahlung von 335 Millionen US-Dollar und kann mehrere Milliarden Dollar an zusätzlichen bedingten Zahlungen, Optionsgebühren, Meilensteinen und gestaffelten Lizenzgebühren verdienen.
Die Partnerschaft vereint AbbVies Expertise in der Entwicklung und Vermarktung biotherapeutischer Arzneimittel mit ADARx' proprietärer RNA-Technologie. Die Zusammenarbeit konzentriert sich auf die Entwicklung von siRNA-Therapeutika, die die Genexpression regulieren, indem sie die Boten-RNA gezielt angreifen, um die Produktion krankheitsverursachender Proteine zu verhindern. Die Technologie von ADARx ermöglicht ein nachhaltiges und präzises mRNA-Silencing, während AbbVie seine Expertise in Antikörpertechnik und Wirkstoffabgabemethoden einbringt.
- Substantial upfront payment of $335 million with potential for billions in additional payments
- Access to ADARx's proprietary RNA technology for developing next-generation therapeutics
- Expansion into promising siRNA therapeutic modality across multiple disease areas
- Strategic combination of complementary expertise between both companies
- Significant financial commitment required from AbbVie
- Early-stage technology with inherent development risks
- Challenges in targeting and delivering siRNA effectively still remain
Insights
AbbVie's $335M deal with ADARx strengthens its RNA therapeutics position, diversifying pipeline with potentially lucrative siRNA technology.
AbbVie's collaboration with ADARx Pharmaceuticals represents a strategic expansion into the growing field of siRNA therapeutics. The
This deal provides AbbVie access to ADARx's proprietary RNA technology platform, potentially addressing key challenges in siRNA development - particularly tissue-specific delivery and sustained gene silencing. These technical hurdles have historically limited siRNA therapeutic applications despite the modality's promising mechanism.
The financial structure is particularly noteworthy - beyond the substantial upfront payment, the agreement includes potential milestone payments potentially reaching several billion dollars plus tiered royalties. This back-loaded compensation structure mitigates AbbVie's immediate financial risk while providing significant incentives to ADARx.
For AbbVie, this partnership represents an important pipeline diversification strategy. The company gains potential new therapeutic candidates across three major disease areas (neuroscience, immunology, and oncology), which directly aligns with AbbVie's existing therapeutic focus. This RNA-based approach complements AbbVie's traditional strengths in antibodies and small molecules, potentially addressing disease targets previously considered undruggable.
The collaboration's value proposition centers on combining complementary expertise - ADARx contributes specialized RNA discovery capabilities and proprietary siRNA technology, while AbbVie brings antibody engineering, ADC expertise, and established research infrastructure. This synergistic approach may accelerate development timelines and increase the probability of clinical success across multiple programs.
- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology
siRNA represents a class of molecules capable of regulating gene expression and protein production. Unlike traditional modalities such as antibodies and small molecules, siRNA regulates the expression of genes. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins.
The strategic collaboration will leverage ADARx's RNA discovery expertise and proprietary siRNA technology, which has the potential to enable sustained and precise mRNA silencing. AbbVie will contribute its expertise in antibody engineering, antibody drug conjugates (ADCs) and tissue delivery approaches as appropriate, to augment ADARx's discovery efforts.
"siRNA is a promising genetic medicine approach for silencing disease-causing genes, but challenges still remain in targeting and delivering siRNA effectively," said Jonathon Sedgwick, Ph.D., senior vice president and global head, discovery research, AbbVie. "We are very pleased to collaborate with ADARx, leveraging their proprietary RNA technology alongside our antibody, ADC, and therapeutic area research and development expertise to bring siRNA forward as a potential novel therapeutic modality alongside our other established approaches. Together, we're committed to developing innovative solutions for difficult-to-treat diseases across neuroscience, immunology and oncology."
"This collaboration with AbbVie further validates the differentiated RNA technology that we have developed at ADARx and has the potential to unlock tremendous clinical and commercial potential across multiple disease areas. AbbVie's research and development expertise combined with its global commercial reach make them the ideal strategic collaborator to accelerate these programs for the potential benefit of patients worldwide," said Zhen Li, Ph.D., co-founder, president and chief executive officer of ADARx. "In addition to this strategic collaboration with AbbVie, ADARx continues to advance a deep pipeline of wholly-owned clinical-stage programs that span complement-mediated, cardiovascular and thrombotic diseases and various preclinical discovery programs including in obesity and neurodegeneration."
Under the terms of the agreement, ADARx will receive a
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter) and YouTube.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late clinical-stage biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. We are focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, initially developing our product candidates for the treatment of complement-mediated, genetic, cardiovascular, central nervous system and metabolic (obesity) diseases. Follow ADARx on LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
AbbVie Media Liz Tang, Ph.D. liz.tang@abbvie.com
Investors Liz Shea liz.shea@abbvie.com | ADARx Media Teri Dahlman, Red House Communications teri@redhousecomms.com
Investors Ajim Tamboli, CFA ir@adarx.com
|
View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-and-adarx-pharmaceuticals-announce-collaboration-and-license-option-agreement-to-develop-next-generation-sirna-therapies-across-multiple-therapeutic-areas-302454426.html
SOURCE AbbVie
FAQ
What is the value of AbbVie's (ABBV) collaboration agreement with ADARx Pharmaceuticals?
What therapeutic areas will AbbVie's (ABBV) collaboration with ADARx focus on?
What technology will AbbVie (ABBV) gain access to through the ADARx partnership?
How will AbbVie (ABBV) contribute to the ADARx collaboration?
What are the main challenges in siRNA therapeutics development mentioned in the AbbVie (ABBV) announcement?
